Description: Kio Medical has developed a software that relies on the susceptibility induced signal loss on T2*-weighted sequences which results from a bolus of gadoliniumbased contrast passing through a capillary bed. The most commonly calculated parameters in this software are rCBV, rCBF, and MTT as dynamic susceptibility contrast-enhanced MR perfusion, still abbreviated to DSC. This software also noninvasively characterizes tumor biology allowing for the diagnosis and therapeutic monitoring of glioma.
Disease: ❖ Solid tumor ❖ Prostate cancer ❖ Rectal cancer ❖ Endometrial cancer ❖ Liver cancer